These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Individual patient data analysis to assess modifications to the RECIST criteria. Bogaerts J; Ford R; Sargent D; Schwartz LH; Rubinstein L; Lacombe D; Eisenhauer E; Verweij J; Therasse P; Eur J Cancer; 2009 Jan; 45(2):248-60. PubMed ID: 19095437 [TBL] [Abstract][Full Text] [Related]
29. A perspective: the integration of ctDNA into Response Evaluation Criteria in Solid Tumours 1.1 for phase II immunotherapy clinical trials. Kus T; Cicin I Immunotherapy; 2024 Mar; 16(5):319-329. PubMed ID: 38197142 [TBL] [Abstract][Full Text] [Related]
30. Comparing RECIST with EORTC criteria in metastatic bladder cancer. Öztürk H J Cancer Res Clin Oncol; 2016 Jan; 142(1):187-94. PubMed ID: 26208817 [TBL] [Abstract][Full Text] [Related]
31. Imaging response assessment in oncology. Curran SD; Muellner AU; Schwartz LH Cancer Imaging; 2006 Oct; 6(Spec No A):S126-30. PubMed ID: 17114065 [TBL] [Abstract][Full Text] [Related]
32. Resisting RECIST-Uniformity Versus Clinical Validity. Wilson MK; Friedlander ML; Lheureux S; Small W; Poveda A; Pujade-Lauraine E; Karakasis K; Bacon M; Bowering V; Chawla T; Oza AM Int J Gynecol Cancer; 2017 Oct; 27(8):1619-1627. PubMed ID: 28692635 [TBL] [Abstract][Full Text] [Related]
33. Pearls and pitfalls of response evaluation criteria in solid tumors (RECIST) v1.1 non-target lesion assessment. Morse B; Jeong D; Ihnat G; Silva AC Abdom Radiol (NY); 2019 Feb; 44(2):766-774. PubMed ID: 30196362 [TBL] [Abstract][Full Text] [Related]
34. Limitations with the response evaluation criteria in solid tumors (RECIST) guidance in disseminated pediatric malignancy. Barnacle AM; McHugh K Pediatr Blood Cancer; 2006 Feb; 46(2):127-34. PubMed ID: 16231313 [TBL] [Abstract][Full Text] [Related]
35. Monitoring response to antiangiogenic treatment and predicting outcomes in advanced hepatocellular carcinoma using image biomarkers, CT perfusion, tumor density, and tumor size (RECIST). Jiang T; Kambadakone A; Kulkarni NM; Zhu AX; Sahani DV Invest Radiol; 2012 Jan; 47(1):11-7. PubMed ID: 21512396 [TBL] [Abstract][Full Text] [Related]
36. ENABLE (Exportable Notation and Bookmark List Engine): an Interface to Manage Tumor Measurement Data from PACS to Cancer Databases. Goyal N; Apolo AB; Berman ED; Bagheri MH; Levine JE; Glod JW; Kaplan RN; Machado LB; Folio LR J Digit Imaging; 2017 Jun; 30(3):275-286. PubMed ID: 28074302 [TBL] [Abstract][Full Text] [Related]
37. Imaging of tumour response to immunotherapy. Dromain C; Beigelman C; Pozzessere C; Duran R; Digklia A Eur Radiol Exp; 2020 Jan; 4(1):2. PubMed ID: 31900689 [TBL] [Abstract][Full Text] [Related]
38. Cancer Imaging in Immunotherapy. Ayoub M; Eleneen Y; Colen RR Adv Exp Med Biol; 2020; 1244():309-324. PubMed ID: 32301025 [TBL] [Abstract][Full Text] [Related]
39. Discrepancy in the assessment of tumor response in patients with pancreatic cancer: WHO versus RECIST criteria. Ahn SH; Garewal HS; Dragovich T J BUON; 2008; 13(3):359-62. PubMed ID: 18979550 [TBL] [Abstract][Full Text] [Related]